PDF(Pubmed)
Abstract：
UNASSIGNED: The ongoing global epidemic of coronavirus disease 2019 (COVID-19) has created a serious public health problem. The selection of safe and effective therapeutic agents is of paramount importance. This systematic review aims to evaluate the efficacy and safety of the combination of casirivimab and imdevimab in the treatment of global cases of COVID-19.
UNASSIGNED: To identify randomized controlled trials (RCTs) investigating the combined administration of casirivimab and imdevimab for COVID-19 management, a comprehensive search was conducted across multiple databases including PubMed, Web of Science, Embase, and the Cochrane Library from their inception to September 10, 2022. Data on the efficacy and safety of casirivimab and imdevimab were extracted. Subgroup analyses and sensitivity analyses were performed.
UNASSIGNED: A total of 851 articles were searched. Twelve studies were finally included in the meta-analysis, with 27,179 participants. Dichotomous and continuous variables were presented as odds ratios (ORs) and weighted mean differences (WMDs) with their 95% confidence intervals (CIs), respectively. Compared to placebo or alternative medications, the combination of casirivimab and imdevimab reduced viral load (WMD: -0.73, 95% CI: -1.09 to -0.38, P<0.01), all-cause mortality (OR =0.90, 95% CI: 0.82-0.99, P=0.03), the incidence of any serious adverse events (OR =0.80, 95% CI: 0.67-0.95, P=0.01), the incidence of Grade 3 or more severe adverse events (OR =0.76, 95% CI: 0.62-0.92, P=0.01), the likelihood of contracting COVID-19, the incidence of hospitalization, emergency room visits, and mortality (OR =0.54, 95% CI: 0.32-0.93, P=0.03).
UNASSIGNED: The monoclonal antibody combination of casirivimab and imdevimab is effective in treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as they can reduce viral load, all-cause mortality, infection rates, and the incidence of clinical outcomes of special interest after treatment, while maintaining a favorable safety profile.
UNASSIGNED: To identify randomized controlled trials (RCTs) investigating the combined administration of casirivimab and imdevimab for COVID-19 management, a comprehensive search was conducted across multiple databases including PubMed, Web of Science, Embase, and the Cochrane Library from their inception to September 10, 2022. Data on the efficacy and safety of casirivimab and imdevimab were extracted. Subgroup analyses and sensitivity analyses were performed.
UNASSIGNED: A total of 851 articles were searched. Twelve studies were finally included in the meta-analysis, with 27,179 participants. Dichotomous and continuous variables were presented as odds ratios (ORs) and weighted mean differences (WMDs) with their 95% confidence intervals (CIs), respectively. Compared to placebo or alternative medications, the combination of casirivimab and imdevimab reduced viral load (WMD: -0.73, 95% CI: -1.09 to -0.38, P<0.01), all-cause mortality (OR =0.90, 95% CI: 0.82-0.99, P=0.03), the incidence of any serious adverse events (OR =0.80, 95% CI: 0.67-0.95, P=0.01), the incidence of Grade 3 or more severe adverse events (OR =0.76, 95% CI: 0.62-0.92, P=0.01), the likelihood of contracting COVID-19, the incidence of hospitalization, emergency room visits, and mortality (OR =0.54, 95% CI: 0.32-0.93, P=0.03).
UNASSIGNED: The monoclonal antibody combination of casirivimab and imdevimab is effective in treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as they can reduce viral load, all-cause mortality, infection rates, and the incidence of clinical outcomes of special interest after treatment, while maintaining a favorable safety profile.
摘要：
■2019年冠状病毒病（COVID-19）的全球流行造成了严重的公共卫生问题。选择安全有效的治疗剂是最重要的。本系统评价旨在评估casirivimab和imdevimab联合治疗COVID-19全球病例的疗效和安全性。
■为了确定随机对照试验（RCT），研究卡西里维单抗和imdevimab联合用于COVID-19管理，在包括PubMed在内的多个数据库中进行了全面搜索，WebofScience,Embase,和Cochrane图书馆从成立到2022年9月10日。提取了casirivimab和imdevimab的疗效和安全性数据。进行亚组分析和敏感性分析。
■共检索了851篇文章。12项研究最终被纳入荟萃分析，27,179人。二分变量和连续变量表示为优势比(OR)和加权平均差(WMD)，其95%置信区间(CI)。分别。与安慰剂或替代药物相比，casirivimab和imdevimab的组合降低了病毒载量（WMD：-0.73，95％CI：-1.09至-0.38，P<0.01），全因死亡率（OR=0.90，95%CI：0.82-0.99，P=0.03），任何严重不良事件的发生率（OR=0.80，95％CI：0.67-0.95，P=0.01），3级或更严重不良事件的发生率（OR=0.76，95％CI：0.62-0.92，P=0.01），感染COVID-19的可能性，住院的发生率，急诊室探视,死亡率（OR=0.54，95%CI：0.32-0.93，P=0.03）。
■casirivimab和imdevimab的单克隆抗体组合可有效治疗感染严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）的患者，因为它们可以减少病毒载量，全因死亡率,感染率,以及治疗后特别感兴趣的临床结果的发生率，同时保持良好的安全性。
■为了确定随机对照试验（RCT），研究卡西里维单抗和imdevimab联合用于COVID-19管理，在包括PubMed在内的多个数据库中进行了全面搜索，WebofScience,Embase,和Cochrane图书馆从成立到2022年9月10日。提取了casirivimab和imdevimab的疗效和安全性数据。进行亚组分析和敏感性分析。
■共检索了851篇文章。12项研究最终被纳入荟萃分析，27,179人。二分变量和连续变量表示为优势比(OR)和加权平均差(WMD)，其95%置信区间(CI)。分别。与安慰剂或替代药物相比，casirivimab和imdevimab的组合降低了病毒载量（WMD：-0.73，95％CI：-1.09至-0.38，P<0.01），全因死亡率（OR=0.90，95%CI：0.82-0.99，P=0.03），任何严重不良事件的发生率（OR=0.80，95％CI：0.67-0.95，P=0.01），3级或更严重不良事件的发生率（OR=0.76，95％CI：0.62-0.92，P=0.01），感染COVID-19的可能性，住院的发生率，急诊室探视,死亡率（OR=0.54，95%CI：0.32-0.93，P=0.03）。
■casirivimab和imdevimab的单克隆抗体组合可有效治疗感染严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）的患者，因为它们可以减少病毒载量，全因死亡率,感染率,以及治疗后特别感兴趣的临床结果的发生率，同时保持良好的安全性。
